INTRODUCTION: We investigated the relationships between treatment characteristics and long-term outcomes in patients with locally advanced thymoma or thymic carcinoma. METHODS: We retrospectively reviewed 146 patients treated from 1980 to 2011 at 2 tertiary cancer care centers, 110 with Masaoka-Koga stages III to IVA invasive thymoma and 36 with stages I to IVA thymic carcinoma. Survival probabilities were estimated using the Kaplan-Meier method. Risk factors related to survival were identified by univariate and multivariate competing risk analysis, with overall survival (OS) as the competing risk. The Cox regression analysis was used to identify risk factors for OS. RESULTS: Median follow-up time for all patients was 64 months. At 5 and 10 years, rates of OS and freedom from recurrence (FFR) were 81% and 58% and 81% and 65%, respectively. Of the patients who underwent surgery, trimodality treatment produced better survival compared with less aggressive treatment among patients with stage III disease (P=0.03). Among patients who underwent trimodality treatment, patients with stage III disease had better OS (P=0.03) and FFR (P<0.001) than those with stage IVA disease. On Cox regression analysis, decreased OS was associated with thymic carcinoma (hazard ratio [HR], 7.36; 95% confidence interval [CI], 2.38-22.77; P=0.001), R2/unresectable disease (HR, 8.45; 95% CI, 1.44-49.42; P=0.02), and an Eastern Cooperative Oncology Group performance score of 1 (HR, 8.14; 95% CI, 1.55-42.75; P=0.01) or 2 to 3 (HR, 29.60; 95% CI, 4.0-218.98; P=0.001) versus 0. CONCLUSIONS: Aggressive treatment with chemotherapy, surgical resection, and postoperative radiation therapy can produce long-term survival for patients with invasive thymic malignancies.
INTRODUCTION: We investigated the relationships between treatment characteristics and long-term outcomes in patients with locally advanced thymoma or thymic carcinoma. METHODS: We retrospectively reviewed 146 patients treated from 1980 to 2011 at 2 tertiary cancer care centers, 110 with Masaoka-Koga stages III to IVA invasive thymoma and 36 with stages I to IVA thymic carcinoma. Survival probabilities were estimated using the Kaplan-Meier method. Risk factors related to survival were identified by univariate and multivariate competing risk analysis, with overall survival (OS) as the competing risk. The Cox regression analysis was used to identify risk factors for OS. RESULTS: Median follow-up time for all patients was 64 months. At 5 and 10 years, rates of OS and freedom from recurrence (FFR) were 81% and 58% and 81% and 65%, respectively. Of the patients who underwent surgery, trimodality treatment produced better survival compared with less aggressive treatment among patients with stage III disease (P=0.03). Among patients who underwent trimodality treatment, patients with stage III disease had better OS (P=0.03) and FFR (P<0.001) than those with stage IVA disease. On Cox regression analysis, decreased OS was associated with thymic carcinoma (hazard ratio [HR], 7.36; 95% confidence interval [CI], 2.38-22.77; P=0.001), R2/unresectable disease (HR, 8.45; 95% CI, 1.44-49.42; P=0.02), and an Eastern Cooperative Oncology Group performance score of 1 (HR, 8.14; 95% CI, 1.55-42.75; P=0.01) or 2 to 3 (HR, 29.60; 95% CI, 4.0-218.98; P=0.001) versus 0. CONCLUSIONS: Aggressive treatment with chemotherapy, surgical resection, and postoperative radiation therapy can produce long-term survival for patients with invasive thymic malignancies.
Authors: Ikenna C Okereke; Kenneth A Kesler; Mohamed H Morad; Deming Mi; Karen M Rieger; Thomas J Birdas; Sunil Badve; John D Henley; Mark W Turrentine; Robert P Nelson; Patrick J Loehrer Journal: Ann Thorac Surg Date: 2010-04 Impact factor: 4.330
Authors: Hsuan Chih Hsu; Eng Yen Huang; Chong Jong Wang; Li Min Sun; Hui Chun Chen Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-01 Impact factor: 7.038
Authors: Edward S Kim; Joe B Putnam; Ritsuko Komaki; Garrett L Walsh; Jae Y Ro; Hyung Ju Shin; Mylene Truong; Hojin Moon; Steven G Swisher; Frank V Fossella; Fadlo R Khuri; Waun K Hong; Dong M Shin Journal: Lung Cancer Date: 2004-06 Impact factor: 5.705
Authors: James Huang; Nabil P Rizk; William D Travis; Gregory J Riely; Bernard J Park; Manjit S Bains; Joseph Dycoco; Raja M Flores; Robert J Downey; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2009-07 Impact factor: 5.209
Authors: Conrad B Falkson; Andrea Bezjak; Gail Darling; Richard Gregg; Richard Malthaner; Donna E Maziak; Edward Yu; Christopher A Smith; Sheila McNair; Yee C Ung; William K Evans Journal: J Thorac Oncol Date: 2009-07 Impact factor: 15.609
Authors: David I Suster; A Craig Mackinnon; Marcello DiStasio; Malay Kumar Basu; German Pihan; Saul Suster Journal: Mod Pathol Date: 2022-02-10 Impact factor: 8.209
Authors: Jane J Keating; Sarah Nims; Ollin Venegas; Jack Jiang; David Holt; John C Kucharczuk; Charuhas Deshpande; Sunil Singhal Journal: Oncotarget Date: 2016-01-19